Clinical Trials Logo

Filter by:
NCT ID: NCT00600886 Active, not recruiting - Acromegaly Clinical Trials

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Start date: February 2008
Phase: Phase 3
Study type: Interventional

The patients will receive either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study is to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization of IGF-1 to within normal limits (age and sex related) between the two treatment groups (pasireotide LAR and octreotide LAR) at 12 months. Following one year of treatment patients may proceed into the study extension. Patients who did not respond to the treatment they were randomized to (based on month 12 assessment results) will be switched to the other treatment arm at month 13.

NCT ID: NCT00430833 Active, not recruiting - Clinical trials for Hypertrophic Cardiomyopathy

CHANCE - Candesartan in Hypertrophic Cardiomyopathy

Start date: n/a
Phase: Phase 2
Study type: Interventional

The primary hypothesis of the study is that treatment with AT1-R antagonist in patients with nonobstructive form of HCM will be first save, second will cause regression of myocardial hypertrophy.

NCT ID: NCT00405756 Active, not recruiting - Clinical trials for Newly Diagnosed Multiple Myeloma

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.

NCT ID: NCT00399035 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

HORIZON II
Start date: November 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.

NCT ID: NCT00375336 Active, not recruiting - Aortic Stenosis Clinical Trials

Risk Factors Associated With Calcification of the Aortic Valve

Start date: January 2005
Phase: N/A
Study type: Observational

The purpose of this study is - to determine the degree of endothelial dysfunction and inflammation in calcific aortic valve disease associated with coronary artery disease(CAD). - to determine whether there is relationship between calcium metabolism and calcific aortic valve disease associated with CAD.

NCT ID: NCT00317408 Active, not recruiting - Lymphoma Clinical Trials

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Start date: April 2004
Phase: N/A
Study type: Interventional

RATIONALE: Giving combination chemotherapy and total-body irradiation before a peripheral stem cell transplant that uses the patient's or a donor's stem cells, helps stop both the growth of cancer cells and the patient's immune system from rejecting the stem cells. When the stem cells are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving combination chemotherapy and total-body irradiation followed by a stem cell transplant may be an effective treatment for anaplastic large cell lymphoma. PURPOSE: This clinical trial is studying how well combination chemotherapy followed by stem cell transplant works in treating young patients with progressive or relapsed anaplastic large cell lymphoma.

NCT ID: NCT00209209 Active, not recruiting - Clinical trials for Lymphoma, Mantle-Cell

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

MCLelderly
Start date: January 14, 2004
Phase: Phase 3
Study type: Interventional

The aim of this study is to answer the following independent questions in the treatment of mantle cell lymphomas: - Can rituximab-fludarabine, cyclophosphamide (R-FC) improve the reduction of lymphoma mass compared to rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) and so become a new standard for initial cytoreductive therapy? - Can maintenance with rituximab substitute the interferon maintenance and even improve the progression free survival in patients after successful initial cytoreductive therapy?

NCT ID: NCT00156741 Active, not recruiting - Clinical trials for Bradycardia; Sick Sinus Syndrome, AV Block

Efficacy of a Pacemaker Algorithm in Promotion of the Intrinsic Heart Activity.

Start date: April 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to provide evidence that the Refined Ventricular Pacing Algorithm leads to clinically relevant reduction (at least 50% reduction) of the incidence of ventricular pacing.

NCT ID: NCT00116805 Active, not recruiting - Chronic Hepatitis B Clinical Trials

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and antiviral activity of tenofovir disoproxil fumarate (TDF, tenofovir DF) compared to adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B. Participants will receive either TDF or the approved hepatitis B therapy ADV. After 48 weeks all participants will be switched to open-label TDF.

NCT ID: NCT00114972 Active, not recruiting - Clinical trials for Coronary Artery Disease

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

SYNTAX
Start date: March 2005
Phase: Phase 3
Study type: Interventional

The SYNTAX trial is designed to determine the best treatment for patients with complex coronary disease (blocked or narrowed arteries in both the right and left sides of the heart) by randomizing patients to receive either percutaneous coronary intervention (PCI) with polymer-based paclitaxel-eluting TAXUS stents or to coronary artery bypass surgery (CABG).